Equibles does not estimate personal net worth.
Get an email with a short summary when Viridian Therapeutics, Inc.\DE publishes a filing, an earnings call transcript or a press release.
Get VRDN alertsScott Myers is recorded as Board Member and CEO at Viridian Therapeutics, Inc.\DE (VRDN) since February 6, 2023. Viridian Therapeutics, Inc.\DE reported in an 8-K filed November 2, 2023 that Scott Myers resigned as member of the board of directors, effective October 29, 2023. Viridian Therapeutics, Inc.\DE reported in an 8-K filed February 6, 2023 that Scott Myers was appointed Class III Director, effective February 6, 2023. Viridian Therapeutics, Inc.\DE reported in an 8-K filed February 6, 2023 that Scott Myers was appointed President and Chief Executive Officer, effective February 6, 2023. The proxy statement of Viridian Therapeutics, Inc.\DE reports total compensation of $36,407,990 for Scott Myers in fiscal 2023, including a base salary of $549,475. Scott Myers has spoken on 1 earnings call across 1 company, most recently for Viridian Therapeutics, Inc.\DE on March 8, 2023. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viridian Therapeutics, Inc.\DE includes Stephen Mahoney (CEO and Board Member), Tomas Kiselak (Chairman), Seth Harmon (CFO) and 7 others.
“On October 29, 2023, Scott Myers resigned as a member of the board of directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), effective immediately.”
“Mr. Myers was also appointed as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified (the “Board”).”
“This is my first quarterly conference call since joining Viridian about a month ago. For those of you who are not familiar with my background, I've spent over 30 years in the pharmaceutical and medical technology space.”
2023-02-06–present
2023-02-06–present
2023-02-06–2023-10-29
Biotechnology · Healthcare
Board Member, CEO
2023-02-06–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Viridian Therapeutics, Inc.\DE (VRDN) | Former President, Chief Executive Officer and Director | $549,475 | $36,407,990 |
